MétaCan
Menu
Back to cohort
Record W4408655766 · doi:10.26685/urncst.774

Overcoming the Blood-Brain Barrier, Strategies and Advances in Therapeutic Delivery: A Literature Review

2025· review· en· W4408655766 on OpenAlexaff
Ursula A. Anirud

Bibliographic record

VenueUndergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · 2025
Typereview
Languageen
FieldMedicine
TopicPharmacological Effects and Toxicity Studies
Canadian institutionsQueen's University
Fundersnot available
KeywordsBlood–brain barrierMedicineIntensive care medicinePsychologyNeuroscienceCentral nervous system

Abstract

fetched live from OpenAlex

The treatment options for disorders affecting the central nervous system (CNS) heavily rely on medications to be delivered to the brain, however diverse and effective treatment options are lacking, especially in Alzheimer’s disease (AD) and brain cancers. The passage of drugs into the brain is challenging, due to limited permeability of the blood-brain barrier (BBB). The BBB is a physiological filter for molecules circulating in the bloodstream, playing an essential role in protecting the brain and maintaining its homeostasis. The endothelial cells constituting the microvasculature of the BBB exhibit characteristics such as high levels of tight junctions, adherens junctions and efflux transport proteins, which, together with the lack of capillary fenestrations, impede the ability of drugs to reach CNS targets. Currently available treatments are limited, with invasive neurosurgical interventions and novel non-invasive delivery strategies. Invasive approaches are challenged by significant adverse events and potentially marginal efficacy. Many new methods open prospects for targeted drug deposition in the brain, each with distinct mechanisms of action. These methods comprehend focused ultrasound-mediated disruption of the BBB, innovative physicochemical drug formulations and intranasal pharmacological administrations. The aim of this review is to provide a critical analysis of the current state of drug delivery across the BBB, comparing existing and emerging technologies in the context of neurodegenerative disorders, in particular AD, and brain cancers. A literature search was performed including articles exploring current and evolving methods for drug delivery across the BBB. Considering epidemiological trends highlighting the growing societal burden of neurodegeneration in aging populations and rising incidence of cancers worldwide, it is essential to explore options for effective drug delivery to the brain. The development and optimization of such innovative drug delivery methods holds significant potential for treating neurological disorders: facilitating the use of large molecules, exhibiting more specific cellular targeting but reduced brain permeability, or expediting the formulation of novel molecules bypassing the physiological systems of the BBB. These strategies can improve therapeutic outcomes, reduce side effects, and enhance the quality of life for patients affected with CNS diseases. Continued research is essential to refine and translate these techniques for clinical use.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.006
Threshold uncertainty score0.019

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0050.005
Science and technology studies0.0000.001
Scholarly communication0.0020.002
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0060.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.076
GPT teacher head0.495
Teacher spread0.418 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueUndergraduate Research in Natural and Clinical Science and Technology (URNCST) JournalSame topicPharmacological Effects and Toxicity StudiesFrench-language works237,207